{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:14:34Z","timestamp":1770448474692,"version":"3.49.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>From 2017 to 2024, there were 16 cases of ceftriaxone-resistant gonorrhoea in Canada, 8 of which were isolated in 2024, including one XDR case. We describe the clinical and demographic details of all 16 cases and examine the phenotypic and molecular characteristics of each case. To investigate the relatedness of the cases both to each other and to international isolates, a phylogenetic tree was constructed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All 16 ceftriaxone-resistant isolates underwent WGS and were compared to the international isolates. Antimicrobial susceptibility testing was completed by agar dilution following the CLSI protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ceftriaxone MICs for the 16 isolates range between 0.25 and 2\u2005mg\/L. All cases were isolated from genital sites, and four cases were probable treatment failures. Ten of the cases were linked to international travel.<\/jats:p>\n                    <jats:p>Seven of the isolates were part of the NG-STAR ST 233 clonal complex. All 16 cases have penA alleles associated with cephalosporin resistance, including penA 60.001, penA 121.002, penA 237.001 and penA 294.002.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We summarize 16 cases of ceftriaxone-resistant gonorrhoea that were isolated in Canada from 2017 to 2024. We determined the penA allele type for each case and detected molecular markers associated with cephalosporin resistance. Local public health investigations and the genomic data for each case indicate that the strains did not spread further in the population. To date, ceftriaxone remains an effective treatment for gonorrhoea, but continued surveillance is required to ensure detection and thus prevent the further spread of ceftriaxone-resistant Neisseria gonorrhoeae in Canada.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag007","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:43:12Z","timestamp":1767876192000},"source":"Crossref","is-referenced-by-count":0,"title":["Summary of ceftriaxone-resistant\n                    <i>Neisseria gonorrhoeae<\/i>\n                    in Canada, 2017\u201324"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7077-7099","authenticated-orcid":false,"given":"Robyn","family":"Thorington","sequence":"first","affiliation":[{"name":"National Microbiology Laboratory Branch, Public Health Agency of Canada , Winnipeg, Manitoba ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman","family":"Barairo","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory Branch, Public Health Agency of Canada , Winnipeg, Manitoba ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6432-9257","authenticated-orcid":false,"given":"Shelley W","family":"Peterson","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory Branch, Public Health Agency of Canada , Winnipeg, Manitoba ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian","family":"Louren\u00e7o","sequence":"additional","affiliation":[{"name":"Centre for Communicable Diseases and Infection Control Branch, Public Health Agency of Canada , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Tran","sequence":"additional","affiliation":[{"name":"Public Health Ontario Laboratory , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Grant","sequence":"additional","affiliation":[{"name":"Bacteriology, BC Centre for Disease Control Public Health Laboratory , Vancouver, British Columbia ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Laboratoire de Sant\u00e9 Publique du Qu\u00e9bec, Ste-Anne-de-Bellevue , Qu\u00e9bec ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanis C","family":"Dingle","sequence":"additional","affiliation":[{"name":"Alberta Precision Laboratories, Provincial Laboratory for Public Health , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Gravel","sequence":"additional","affiliation":[{"name":"Centre for Communicable Diseases and Infection Control Branch, Public Health Agency of Canada , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Martin","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory Branch, Public Health Agency of Canada , Winnipeg, Manitoba ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"2026020510355996000_dkag007-B1","author":"Public Health Agency of Canada"},{"key":"2026020510355996000_dkag007-B2","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1016\/S2666-5247(21)00171-3","article-title":"WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017\u201318: a retrospective observational study","volume":"2","author":"Unemo","year":"2021","journal-title":"Lancet Microbe"},{"key":"2026020510355996000_dkag007-B3","author":"Public Health Agency of Canada"},{"key":"2026020510355996000_dkag007-B4","volume-title":"Updated Recommendations for the Treatment of Neisseria gonorrhoeae, Chlamydia trachomatis and Treponema pallidum (Syphilis), and new Recommendations on Syphilis Testing and Partner Services","author":"World Health Organization","year":"2024"},{"key":"2026020510355996000_dkag007-B5","author":"Ohnishi"},{"key":"2026020510355996000_dkag007-B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/IM9.0000000000000113","article-title":"Global transmission of the penA allele 60.001\u2013containing high-level ceftriaxone-resistant gonococcal FC428 clone and antimicrobial therapy of associated cases: a review","volume":"5","author":"van der Veen","year":"2023","journal-title":"Infect Microbes Dis"},{"key":"2026020510355996000_dkag007-B7","author":"Lefebvre"},{"key":"2026020510355996000_dkag007-B8","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2026020510355996000_dkag007-B9","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/infdis\/jiad258","article-title":"Antimicrobial resistance profiling and genome analysis of the penA-60.001 Neisseria gonorrhoeae clinical isolates in China in 2021","volume":"228","author":"Tang","year":"2023","journal-title":"J Infect Dis"},{"key":"2026020510355996000_dkag007-B10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/OLQ.0000000000001710","article-title":"Disseminated gonococcal infections in Manitoba, Canada: 2013 to 2020","volume":"49","author":"Sawatzky","year":"2022","journal-title":"Sex Transm Dis"},{"key":"2026020510355996000_dkag007-B11","volume-title":"CLSI M100: Performance Standards for Antimicrobial Susceptibility Testing","author":"Clinical Laboratory Standards Institute","year":"2025","edition":"35th edn"},{"key":"2026020510355996000_dkag007-B12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/OLQ.0b013e3181bf575c","article-title":"Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007","volume":"37","author":"Brown","year":"2010","journal-title":"Sex Transm Dis"},{"key":"2026020510355996000_dkag007-B13","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/00007435-199607000-00004","article-title":"A clinical isolate of Neisseria gonorrhoeae with in vitro resistance to erythromycin and decreased susceptibility to azithromycin","volume":"23","author":"Ehret","journal-title":"Sex Transm Dis"},{"key":"2026020510355996000_dkag007-B14","author":"Berenger"},{"key":"2026020510355996000_dkag007-B15","doi-asserted-by":"crossref","DOI":"10.14745\/ccdr.v51i101112a06","volume-title":"Detection of Non-travel-Associated, Ceftriaxone Non-susceptible Neisseria gonorrhoeae FC428-Like Harbouring the Mosaic penA60 Allele in Ontario","author":"Komorowski","year":"2025"},{"key":"2026020510355996000_dkag007-B16","author":"Lefebvre"},{"key":"2026020510355996000_dkag007-B17","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1093\/jac\/dkae369","article-title":"Ceftriaxone-resistant Neisseria gonorrhoeae detected in England, 2015\u201324: an observational analysis","volume":"79","author":"Fifer","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026020510355996000_dkag007-B18","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1016\/S1473-3099(24)00486-9","article-title":"Emergence of an extensively drug-resistant Neisseria gonorrhoeae clone","volume":"24","author":"van Hal","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026020510355996000_dkag007-B19","author":"Ouk"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag007\/66783295\/dkag007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag007\/66783295\/dkag007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:36:02Z","timestamp":1770305762000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag007\/8464582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag007","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,2]]},"article-number":"dkag007"}}